Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.
Saved in:
| Title: | Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms. |
|---|---|
| Authors: | Liu XI; Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA., Green DJ; Office of Pediatric Therapeutics, US Food and Drug Administration, Silver Spring, MD, USA., van den Anker J; Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA., Calderon J; Division of Maternal-Fetal Medicine, Department of OB/Gyn, George Washington University, Washington, DC, USA., Ahmadzia H; Division of Maternal-Fetal Medicine, Department of OB/Gyn, George Washington University, Washington, DC, USA., Burckart GJ; Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USA., Dallmann A; Bayer HealthCare SAS, Loos, France, on behalf of: Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer, AG, Germany. |
| Source: | Journal of clinical pharmacology [J Clin Pharmacol] 2024 Nov; Vol. 64 (11), pp. 1443-1455. Date of Electronic Publication: 2024 Jul 08. |
| Publication Type: | Journal Article; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
